



Theratechnologies Announces US\$40 Million Bought-Deal Public Offering Of Units

Janvier 11, 2021

Montreal, QC – January 11, 2021 – Theratechnologies Inc. (“**Theratechnologies**” or the “**Company**”) (TSX: TH) (NASDAQ: THTX) , a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an agreement with a syndicate of Canadian underwriters (collectively, the “**Underwriters**”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 14,546,000 units of the Company (the “**Units**”) for aggregate gross proceeds to the Company of US\$40,001,500 (equivalent to approximately C\$51,081,915) (the « **Offering** ») at a price of US\$2.75 per Unit (equivalent to approximately C\$3.51 per Unit).

Each Unit shall be comprised of one common share of the Company (each a « **Common Share** ») and one-half of one Common Share purchase warrant of the Company (each whole warrant, a « **Warrant** »). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of US\$3.18 (equivalent to approximately C\$4.06) at any time up to 36 months from the closing of the Offering.